Cancer is currently viewed as a disease of evolving genomic instability and abnormal 
deaminase with strong 5 0 -TC preference has recently been exploited:
the U-shaped conformation of ssDNA with the specificity-conferring -1 thymidine (T) base flipped out, and targeted cytidine (C) resides in a zinc-coordinated active size pocket, the T can fit into a groove between flexible loops and make direct hydrogen bonds with APO-BEC3B enzyme, 9 while APOBEC3A binds to ssDNA with TCG preference. 9 APOBEC3B was previously detected as a major mutator deaminase in multiple types of cancer. 10 Extended study in a yeast model and 6 different types of cancer showed that APOBEC3A-like tumors have significantly greater APOBEC-signature (YTCA, Y = pyrimidine) mutations than APOBEC3B-like tumors (RTCA, R = purine), 11 suggesting that APOBEC3A is the predominant mutagenic deaminase in certain types of cancer. The structure of APOBEC3F catalytic domain differs from other APOBEC deaminases in that the zinc is not required for the structural integrity of APOBEC3F.
12
APOBEC3 proteins are localized in the cytoplasm or nuclei depending on the features of individual proteins. AID and APOBEC1 localize mainly in the cytoplasm but act in the nuclei; APOBEC2, APOBEC3A, and APOBEC3C appear to reside in both cytoplasm and nuclei; APOBEC3B is predominantly located in the nucleus, 13 possibly because APOBEC3B protein contains a nuclear localization sequence, and is able to actively enter nuclei. 14 APOBEC3G is located in the cytoplasm against exogenous retroviruses. Thus, cells regulate APOBEC enzymatic activities through protein localizations. selective deamination for methylated cytidines (mC) during epigenetic regulation such as APOBEC3A. 15 We describe their functions in more detail below.
| FUN CTION S OF APOBEC FAMILY GEN ES
Activation-induced deaminase is the oldest member of the APO-BEC family and is essential for antigen-driven B-cell differentiation, antibody affinity maturation and diversification. 16 
| APOBEC FAMILY GENES AND CANCER
Association between APOBEC and carcinogenesis is evidenced from Increasing evidence show that a germline APOBEC3B deletion resulting in an APOBEC3A_APOBEC3B fusion variant increases the risk of breast cancer 39, 40 and increases tumor mutational burden. 41 Recent studies support that APOBEC3 activities are associated with tumorigenesis as a result of increased mutagenesis. In particular, APOBEC3B overexpressed in several human cancer types correlates with the presence of APOBEC3B mutational signature. 10, 42 From whole exome sequence data analysis over 30 different types of cancer, a unique APOBEC3 mutational signature has been identified with cytosine mutation biases, particularly C to T transitions and C to G transversion, and predominantly in TCA or TCT trinucleotide contexts. 10, [42] [43] [44] The APOBEC3B-mediated mutational signature is often associated with breakpoint rearrangement in general, and HER2-enriched subtype of breast cancer. 42 Further analysis showed that APOBEC-signature mutation load in cancer exons is statistically correlated with APOBEC3A and APOBEC3B transcript abundance. 10, 42 Although APOBEC3B mRNA abundance tends to be greater than that of APOBEC3A in cancer samples, APOBEC3A presents a much greater potent inducer of DNA damage. APOBEC3A expression with uracil N-glycosylase inhibition is responsible for HPV16 genome integration and hypermutations in oropharyngeal cancers. 50 Mechanism of viral oncoprotein E6/E7-mediated elevated APOBEC3B expression is due to removal of p53-mediated repression of APOBEC3B expression. 51 Interestingly, the promoter regions of APOBEC3 genes contain p53-binding sites; p53 protein is a major transcriptional regulator of APOBEC3 genes in response to chromosomal stress, and p53 activation increases several APOBEC3 mRNAs and protein expression in a cellular context, except for APO-BEC3B expression in a suppressive method. 52 In contrast to wildtype p53 activation, p53 hotspot mutants upregulate APOBEC3B expression in cancer cells. 52 Therefore, inactivation of p53 by viral protein E6/E7 activation or loss of function of p53 mutations can activate APOBEC3B function, increase genome instability and promote tumor initiation.
Nuclear factor kappa B signaling pathway plays a crucial role in the transcriptional regulation of APOBEC genes such as AID expression. 34, 35 A recent study showed that NF-jB could bind to multiple promoter regions of the APOBEC3B gene and upregulate the expression of APO-BEC3B mRNA under a variety of conditions (eg, PKC/IKK activation, oncogenic activation and IFN treatment). 53 NF-jB may cross-talk with other oncogenic pathways to also upregulate APOBEC3B expression;
for instance, DNA replication stress with a variety of stimulators can activate transcription of APOBEC3B through the ATR/Chk1-dependent pathway. 54 Several oncogenic signaling pathways such as PI3K, MAPK,
AKT and mammalian target of rapamycin (mTOR) pathways are on the circuits of replication stress-induced APOBEC3B activation. 54 These signaling pathways are upstream molecules of the NF-jB pathway; thus we speculate that NF-jB may participate in replication stress-mediated 
| APOBEC3 AS PROGNOSTIC MARKE RS AND THERAPEUTIC TARGE TS FOR CANCER TRE ATMENT
Accumulated evidence has shown that APOBEC3A and APOBEC3B
are the main sources of somatic mutagenesis in human tumors, and APOBEC-mediated mutagenesis is correlated with APOBEC mRNA levels. 42 How the APOBEC mRNA expression is associated with tors for APOBEC3A and APOBEC3B is under consideration. 61 Here we propose two strategies to inhibit AID, APOBEC3A and APO-BEC3B enzymatic activities for cancer intervention. One is for direct inhibition using chemicals or biological approaches including shRNA or clustered regularly interspaced short palindromic repeats (CRISPR)
technology. The mechanism of action of APOBEC enzymes is that these enzymes deaminate cytidine to uridine on RNA/ssDNA, and blocking the interaction between APOBEC and RNA/ssDNA substrates could alleviate unwanted mutations in the genome. Recent release of APOBEC3A-ssDNA and APOBEC3B-ssDNA co-crystal structure will provide a foundation for structurally based design of APOBEC3 small molecule inhibitors. 9, 62 Depletion of APOBEC3B mRNA with siRNA can reverse APOBEC3B-mediated tamoxifen resistance in ER+ breast cancers. 48 MicroRNAs have been reported to negatively regulate APOBEC3 genes, 55 
| SUMMARY AND FUTURE
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